Brokerages Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Price Target at $57.60

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has been given a consensus recommendation of “Buy” by the eleven analysts that are covering the stock, MarketBeat reports. Ten equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $58.20.

Several research analysts have weighed in on the company. Citigroup boosted their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. HC Wainwright boosted their target price on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Finally, Robert W. Baird increased their price target on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a research note on Thursday, February 27th.

Mirum Pharmaceuticals Stock Down 2.7 %

Shares of MIRM stock opened at $43.42 on Friday. The firm’s fifty day moving average price is $47.18 and its two-hundred day moving average price is $43.47. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals has a 1 year low of $23.14 and a 1 year high of $54.23. The firm has a market capitalization of $2.13 billion, a P/E ratio of -21.50 and a beta of 1.04.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The company had revenue of $99.41 million during the quarter, compared to analyst estimates of $96.64 million. On average, equities analysts predict that Mirum Pharmaceuticals will post -1.43 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Jolanda Howe sold 750 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total transaction of $32,115.00. Following the completion of the sale, the senior vice president now owns 2,926 shares in the company, valued at approximately $125,291.32. This trade represents a 20.40 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Peter Radovich sold 2,627 shares of the company’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $48.22, for a total transaction of $126,673.94. Following the completion of the transaction, the chief operating officer now owns 26,961 shares in the company, valued at approximately $1,300,059.42. This trade represents a 8.88 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 40,915 shares of company stock valued at $1,897,920 over the last ninety days. 22.87% of the stock is currently owned by company insiders.

Institutional Trading of Mirum Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Jones Financial Companies Lllp grew its holdings in Mirum Pharmaceuticals by 100.0% in the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company’s stock valued at $30,000 after buying an additional 357 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Mirum Pharmaceuticals in the fourth quarter valued at about $35,000. GF Fund Management CO. LTD. acquired a new position in shares of Mirum Pharmaceuticals in the fourth quarter valued at about $42,000. Mirae Asset Global Investments Co. Ltd. increased its position in Mirum Pharmaceuticals by 22.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock worth $67,000 after acquiring an additional 318 shares during the period. Finally, R Squared Ltd acquired a new stake in Mirum Pharmaceuticals in the 4th quarter worth about $69,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.